Skip to main content

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

Active, not recruiting · NCT01357668

Conditions: Juvenile Idiopathic Arthritis

At a glance

Research payments reported, 2025
$173,478
U.S. investigators named
16
Sites paid
17
Planned or actual enrollment
800

About the trial

Sponsor
Bristol-Myers Squibb
Dates
Started 2013-01-30; completion 2029-01-02
Results posted
Not yet

The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

From ClinicalTrials.gov, last updated 2025-09-25. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $173,478 in research payments for this study in 2025 (18 payments).

Products named: Orencia

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.